ArticleOdontology2022

Bevacizumab and sunitinib mediate osteogenic and pro-inflammatory molecular changes in primary human alveolar osteoblasts in vitro.

Elena Hofmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.